A Phase 2b, Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Tralokinumab in Adult Subjects With Moderate-to-Severe Atopic Dermatitis
Phase of Trial: Phase II
Latest Information Update: 23 Mar 2017
At a glance
- Drugs Tralokinumab (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors MedImmune
- 03 Mar 2017 According to LEO Pharma media release, results will be presented at the American Academy of Dermatology (AAD) meeting 2017.
- 03 Mar 2017 Results published in the LEO Pharma Media Release.
- 01 Jul 2016 Top-line results published in a Leo Pharma media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History